Connection
Jawahar Mehta to Sulfonamides
This is a "connection" page, showing publications Jawahar Mehta has written about Sulfonamides.
|
|
Connection Strength |
|
 |
|
 |
|
1.445 |
|
|
|
-
Kang BY, Wang W, Palade P, Sharma SG, Mehta JL. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol. 2009 Oct; 54(4):327-34.
Score: 0.312
-
Kang BY, Mehta JL. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther. 2009 Dec; 14(4):283-91.
Score: 0.310
-
Khaidakov M, Wang W, Khan JA, Kang BY, Hermonat PL, Mehta JL. Statins and angiogenesis: is it about connections? Biochem Biophys Res Commun. 2009 Sep 25; 387(3):543-7.
Score: 0.307
-
Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006 Feb; 184(2):295-301.
Score: 0.232
-
Chen J, Li D, Schaefer RF, Mehta JL. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol. 2004 Oct; 44(4):446-52.
Score: 0.220
-
Marwali MR, Mehta JL. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost. 2006 Oct; 96(4):401-6.
Score: 0.063